MENU

Marc C. Smaldone, MD, MSHP, FACS

Marc Smaldone, MD, MSHP

Clinical Locations

Primary Location

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111

Secondary Location

Fox Chase Cancer Center East Norriton-Hospital Outpatient Center
2701 Dekalb Pike
East Norriton, PA 19401

About

Associate Professor, Department of Surgical Oncology

Kidney, Bladder, and Prostate Cancer TRDG Member

NCCN, Prostate Cancer Early Detection Panel Member

Treatment Focus

  • Robotic and laparoscopic minimally invasive surgery
  • Continent urinary diversion
  • Salvage and reconstructive Surgery

Research Program

Treatment Philosophy

I am a urologic oncologist specializing in the surgical management of tumors of the kidney, bladder, prostate, adrenal, testis and other genitourinary organs. As part of the multi-disciplinary Genitourinary Cancer Patient Care Team, I work closely with my colleagues in Medical and Radiation Oncology to develop a comprehensive treatment plan that offers the best chance for cure for each patient.

The mission at the Fox Chase Cancer Center is to deliver world class oncologic care in the most compassionate and respectful way possible. A cancer diagnosis brings fear and uncertainty for patients and their families, and my personal philosophy is to treat patients how I would wish for my family members to be treated. Patient education is essential, and I consider it of utmost importance to take the time necessary for patients to understand and feel comfortable with all possible treatment options to inspire confident decision making.

I have expertise in open, laparoscopic, and robotic surgical techniques, which allows me to tailor a specific treatment plan based on individual patient need and preferences. I have particular expertise in minimally invasive organ preserving and reconstructive techniques to preserve function and quality of life, including nerve-sparing prostatectomy for patients with prostate cancer and partial nephrectomy for patients with kidney cancer. I have experience performing both robotic and open cystectomy for patients with bladder cancer, and prefer to construct continent urinary diversions whenever possible. I have a clinical interest in the surgical management of patients with high risk and advanced disease, and have experience performing retroperitoneal lymph node dissection following chemotherapy in patients with testicular cancer, cytoreductive nephrectomy and thrombectomy for patients with metastatic kidney cancer or tumors extending into the vena cava, and salvage surgery following radiation for patients with bladder or prostate cancer.

Follow on Twitter: @FCUroOnc

Education and Training

Educational Background

  • Fellowship: Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA
  • Residency: Urologic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA
  • MS, Health Policy Research, University of Pennsylvania, Philadelphia, PA
  • MD, State University of New York at Stony Brook School of Medicine, Stony Brook, NY

Certifications

  • American Board of Urology

Memberships

  • National Comprehensive Cancer Network (NCCN)
    • Prostate Cancer Early Detection Panel
  • American Urological Association
  • Society of Urologic Oncology
Patient Stories

John Mullarkey, Jr.

Prostate Cancer

John Mullarkey, Jr.

Prostate Cancer

I have always been proactive about my health and started having annual prostate exams when I turned 50 in 2007. My first report was great and showed that my PSA level was undetectable.

Debra Getz

Kidney Cancer

Debra Getz

Kidney Cancer

Debra underwent a successful right nephrectomy, IVC thrombectomy, adrenalectomy, and retroperitoneal lymph node dissection to treat her metastatic kidney cancer.

Sister Marcille McEntee

Skin Cancer;  Ureteral Cancer

Sister Marcille McEntee

Skin Cancer;  Ureteral Cancer

Her gastroenterologist performed a PET scan which revealed a rare kind of cancer, a mucosal melanoma. “At that point, my urologist admitted 'this is beyond me. You need to go somewhere else',” she recalled.

Chuck Leonard

Kidney Cancer

Chuck Leonard

Kidney Cancer

In August 2012, at the age of 61, Chuck Leonard was diagnosed with stage four kidney cancer that had metastasized to his lungs. After seeing one doctor, Chuck decided to seek a second opinion from a specialist at Fox Chase Cancer Center, where he planned to take part in a clinical trial. However, additional testing revealed he was a candidate for surgery. Chuck also underwent radiation using Cyberknife technology at Fox Chase Buckingham after an MRI revealed the kidney cancer had spread to his brain. “In 2016, I can mark three years since I have had detectable cancer,” he said. “I’m so thankful for all the outstanding care, both medical and other, provided by Fox Chase and the caring doctors and nurses. Hopefully, my tests will continue to have good outcomes, and, if not, I know I’m getting the best care possible from Fox Chase Cancer Center.”

Michael Laurenzi

Kidney Cancer;  Pancreatic Cancer

Michael Laurenzi

Kidney Cancer;  Pancreatic Cancer

'I am very lucky the tick bit me, because I had no symptoms and no idea that I had cancer. I have nothing but the highest regard for those doctors and their teams. They are so caring and compassionate, and they literally gave me my life back.'

Pages

Research Profile

Research Program

Research Interests

  • Quality of care
  • Comparative effectiveness
  • Risk assessment
  • Access disparities
  • Surgical outcomes
  • Health services research
Publications

Selected Publications

Correa AF, Handorf E, Joshi SS, Geynisman DM, Kutikov A, Chen DY, Uzzo RG, Viterbo R, Greenberg RE, Smaldone MC. Differences in Survival Associated with Performance of Lymph Node Dissection in Patients with Invasive Penile Cancer: Results from the National Cancer Database. J Urol, 199(5):1238-44, 2018. PubMed

Goel N, Manstein SM, Ward WH, DeMora L, Smaldone MC, Farma JM, Uzzo RG, Esnaola NF. Does the Surgical Apgar Score predict serious complications after elective major cancer surgery? Journal of Surgical Research, 231:242-7, 2018. 

Smaldone, M.C., Corcoran, A.T., Hayn M.H., Konety, B.R., Hrebinko Jr., R.L., Davies, B.J. (2009). Estimation of mortality and morbidity risk in patients undergoing radical cystectomy with continent diversion using the POSSUM and Portsmouth POSSUM predictor equations. J Urol,182(6): 2619-24. PubMed

Smaldone, M.C., Cowan, J., Carroll, P.R., Davies, B.J. (2010). Comparison of eligibility for active surveillance and pathologic outcomes in men undergoing radical prostatectomy in a large community-based cohort. J Urol,183(1):138-43. PubMed

Kutikov, A., Smaldone, M.C., Egleston, B.L., Manley, B.J., Simhan, J., Boorjian, S.A., Viterbo, R., Chen, D.Y., Greenberg, R.E., Uzzo, R.G. (2011). Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephromety Score. Eur Urol, 60(2): 241-8. PubMed

Smaldone, M.C., Kutikov, A., Egleston, B., Simhan, J., Canter, D.J., Teper, E., Viterbo, R., Chen, D.Y., Greenberg, R.E., Uzzo, R.G. (2012). Assessing performance trends in laparoscopic nephrectomy and nephron sparing surgery for localized renal tumors. Urology, 80(2): 286-92. PubMed

Smaldone, M.C., Kutikov, A., Egleston, B.L., Canter, D.J., Viterbo, R., Chen, D.Y., Jewett, M.A., Greenberg, R.E., Uzzo, R.G. (2012). Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer, 118(4):997-1006. PubMed

Smaldone, M.C., Egleston, B.L., Uzzo, R.G., Kutikov, A. (2012). Does partial nephrectomy result in a durable overall survival benefit in the Medicare population? J Urol 188(6): 2089-94. PubMed

Kutikov, A., Egleston, B.L., Canter, D., Smaldone, M.C., Wong, Y.N., Uzzo, R.G. (2012). Competing risks of death in patients with localized renal cell carcinoma: a comorbidity based model. J Urol, 188(6): 2077-83. PubMed

Smaldone, M.C., Simhan, J., Kutikov, A., Canter, D.J., Starkey, R., Zhu, F., Nielsen, M.E., Stitzenberg, K.B., Greenberg, R.E., Uzzo, R.G. (2013) Trends in regionalization of radical cystectomy in three large northeastern states from 1996 to 2009. Urol Oncol, 31(8): 1663-9. PubMed

Tomaszewski, J.J., Uzzo, R.G., Handorf, E.A., Bekelman, J.E., Corcoran, A.T., Kutikov, A., Mehrazin, R., Smaldone, M.C. (2014) Care transitions between hospitals are associated with treatment delays for patients with muscle invasive bladder cancer. J Urol, 192(5): 1349-54. PubMed

Kim, S.P, Gross, C.P., Nguyen, P.L., Smaldone, M.C., Shah, N.D., Karnes, R.J., Thompson, R.H., Hand, L.C., Yu, J.B., Trinh, Q.D., Ziegenfuss, J.Y., Sun, M., Tilburt, J.C. (2014) Perceptions of active surveillance and treatment recommendations for low-risk prostate cancer: Results from a national survey of radiation oncologists and urologists. Med Care, 52(7):579-85. PubMed

Martin, J.M., Handorf, E.A., Kutikov, A., Uzzo, R.G., Bekelman, J.E., Horwitz, E.M., Smaldone, M.C. (2014) The rise and fall of prostate brachytherapy: Use of brachytherapy in the treatment of localized prostate cancer in the National Cancer Database. Cancer, 120(14):2114-21. PubMed

Corcoran, A.T., Handorf, E, Canter, D, Tomaszewski, J.J., Bekelman, J.E., Kim, S.P., Uzzo, R.G., Kutikov. A, Smaldone, M.C. (2015) Variation in performance of candidate surgical quality measures for muscle invasive bladder cancer by hospital type. BJU Int, 115(2):230-7. PubMed

Wang, E.H., Gross, C.P., Tilburt, J.C., Yu, J.B., Nguyen, P.L., Smaldone, M.C., Shah, N.D., Abouassally, R., Sun, M., Kim, S.P. Shared decision making and use of decision AIDS for localized prostate cancer: perceptions from radiation oncologists and urologists. (2015) JAMA Intern Med, 175(5):792-9. PubMed

Additional Publications

My NCBI

Ratings

190 PATIENT SATISFACTION REVIEWS

Our Patient Satisfaction Rating is an average of all responses to care provider related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Learn more.

OVERALL RATING

4.9 / 5.0

RATINGS BREAKDOWN

  • 4.9
  • 4.9
  • 5.0
  • 5.0
  • 4.9

30 PATIENT COMMENTS

  • 5.0
    January 29, 2019
    I had a good experience with Dr. Smaldone, at his office.
  • 5.0
    January 06, 2019
    Dr. Smaldone is a caring, professional, and excellent physician. His interaction with me and my family has been beyond expectations. There really are no words to describe what he has done for me. You are extremely fortunate to have him. The best doctor I have ever worked with. He is the best, bar none. We are so lucky to have him.
  • 5.0
    January 02, 2019
    [...] I always received excellent care.
  • 5.0
    January 01, 2019
    Doctor Smaldone is one of the most caring, knowledgeable and accessible doctor I have met.
  • 5.0
    January 01, 2019
    Mark Smaldone has always showed the upmost interest in my health care . Would recommend him highly.
  • 5.0
    November 18, 2018
    Dr. Smaldone is always professional, patient, caring and helpful. I recommend him to anyone who needs urologic care.
  • 5.0
    November 16, 2018
    I would recommend Dr. Smaldone to others needing prostate cancer surgery. I was diagnosed in June with prostate cancer by another doctor, and Dr. Smaldone was able to schedule me for surgery very promptly.
  • 5.0
    November 15, 2018
    Dr. Marc Smaldone was an absolute pleasure. Although my condition is serious, Dr Smaldone gave me comfort and allowed me to feel a sense of ease and confidence that together we will overcome my cancer. I have all the confidence in him to assist me in getting back to normal health.
  • 5.0
    October 23, 2018
    Far superior to my prior Urologist! Could have used info on what side effects to watch for with Flomax.
  • 5.0
    October 11, 2018
    All very good.
  • 5.0
    October 04, 2018
    Doctor Smaldone is a wonderful doctor. I am so happy I went to Fox Chase and he was assigned to me.
  • 5.0
    October 02, 2018
    I was recommending other to him and Fox Chase
  • 5.0
    October 02, 2018
    The Dr. is great, I have great confidence in his capabilities.
  • 5.0
    September 27, 2018
    3 1/2 years ago he is the ONLY doctor that I saw who LISTENED TO ME
  • 5.0
    September 13, 2018
    --- The Urologist and his staff are wonderful and understanding persons -- All treatments are fully explained ---
  • 5.0
    September 03, 2018
    VERY GOOD EXPERIENCE.
  • 5.0
    August 30, 2018
    Dr Smaldone provided more information than two previous urologists combined. He made my decision to pursue treatment easy.
  • 5.0
    August 07, 2018
    always a pleasure to talk to Dr. Marc Smaldone
  • 5.0
    August 02, 2018
    Dr. Smaldone is the best.
  • 5.0
    July 26, 2018
    I was very impressed with Dr. Smaldone and his staff. My confidence in him and his staff eased a lot of my worries.
LOAD MORE

Connect with Fox Chase